The standout fact from the recent study data is the efficacy of adding OncoSil to the chemotherapy regimen for patients with unresectable locally advanced pancreatic cancer. This combination has resulted in a substantial decrease in tumour size for many patients.
Impressively, 57% of those treated saw their tumour volume reduce by over half. This finding is particularly crucial considering that traditionally, only about 15% of pancreatic cancer patients are eligible for surgical resection, which is the only potentially curative option. With this treatment, one in three patients with previously inoperable LAPC were able to undergo surgery with curative intent. This means a huge leap forward in the management and potential outcomes of pancreatic cancer, which historically has had very few effective treatment options. Great work OncoSil.
Page 7 of the presentation to the AGM that was held on the 29th of Nov: https://www.marketindex.com.au/asx/osl/announcements/presentation-to-annual-general-meeting-2A1490891
Add to My Watchlist
What is My Watchlist?
